Company intelligence / Profile preview

Blue Blood Biotech Corp.

Taipei City, Taipei City, Taiwanblueblood.com.tw ↗

Ownership: Private
Employees: ~10
Development stage: Phase 2

Overview

BB‑101 (recombinant human novel epidermal growth factor, rhNEGF) has completed Phase 1 trials showing safety and efficacy in improving diabetic foot ulcer size. A Phase 2 trial is ongoing as of May 2024. The company has also developed plasma-derived IVIG products at the preclinical stage targeting cytomegalovirus infections. Cosmetic microneedle products have reached commercial production.

Therapeutic areas: ImmunologyMen's HealthEndocrinologyInfectious Diseases
Modalities: Plasma-derived proteinsRecombinant proteinsDiagnostic reagentsMicroneedle technology for cosmetic and medical use
Industry: Biotech

Drug pipeline

2 assets

BB-101

Phase 2

Indications: Diabetic foot ulcers

1 more asset in the full pipeline.

Request access →

Partnerships

Dow Pharmaceuticals Sciences (GMP manufacturing partnership)collaborations with National Cheng Kung University & National Taiwan University on R&DSanar Biotech licensed male pattern baldness technology

Beyond the preview

Go deeper on Blue Blood Biotech Corp..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Blue Blood Biotech Corp..

Explore the full profile